Interv Akut Kardiol 2012; 11(5-6): 197-200

Coming soon: prasugrel, ticagrelor and STEMI

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Treatment with prasugrel and ticagrelor can decrease substantially ischemic complications of acute coronary syndromes, but the rise

in major bleeding complications is not negligible. However, in STEMI patients the positive effect of prasugrel and ticagrelor is more

expressed, and bleeding complications are not different from conventional therapy. This treatment may become first-line treatment of

STEMI patients during primary coronary angioplasty.

Keywords: STEMI, prasugrel, ticagrelor, primary angioplasty

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Coming soon: prasugrel, ticagrelor and STEMI. Interv Akut Kardiol. 2012;11(5-6):197-200.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wiviott SD, Braunwald E, Mc Cabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. Go to original source... Go to PubMed...
    2. Wallentin L, Becker RC, Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. Go to original source... Go to PubMed...
    3. Chen ZM, Jiang LX, Chen YP. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction. Lancet 2005; 366: 1607-1621. Go to original source... Go to PubMed...
    4. Sabatine MS, Cannon CP, Gibson CM. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. Go to original source... Go to PubMed...
    5. Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet 2012; 51: 429-442. Go to original source... Go to PubMed...
    6. Deeks ED. Ticagrelor. Drugs 2011; 71: 909-933. Go to original source... Go to PubMed...
    7. Damman P, Woudstra P, Kuijt WJ. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 2012; 33: 143-153. Go to original source... Go to PubMed...
    8. Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med 2010; 170: 1078-1080. Go to original source... Go to PubMed...
    9. Kaul S, Diamond GA. Prasugrel and cancer. Arch Intern Med 2010; 170: 1010-1012. Go to original source... Go to PubMed...
    10. Montalescot G, Wiviott SD, Braunwald E. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38). Lancet 2009; 373: 723-731. Go to original source... Go to PubMed...
    11. Steg PG, James S, Harrington RA. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention. Circulation 2010; 122: 2131-2141. Go to original source... Go to PubMed...
    12. Bellemain-Appaix A, Brieger D, Beygui F. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 2010; 56: 1542-1551. Go to original source... Go to PubMed...
    13. Arnold SV, Cohen DJ, Magnuson EA. Cost-effectiveness of oral antiplatelet agents - current and future perspectives. Nat Rev Cardiol 2011; 8: 580-591. Go to original source... Go to PubMed...
    14. Lim GB. Treatment with ticagrelor for 12 months after ACS is cost-effective. Nat Rev Cardiol 2012; Jul 10: Epub ahead of print. Go to original source... Go to PubMed...
    15. Osmančík P, Paulů P, Toušek P. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. J Thromb Thrombolysis 2012; 33: 349-354. Go to original source... Go to PubMed...
    16. Osmančík P, Jirmář R, Hulíková K. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158-166. Go to original source... Go to PubMed...
    17. James SK, Storey RF, Khurmi NS. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012; 125: 2914-2921. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.